13 Most Promising Growth Stocks According to Analysts

1. Corcept Therapeutics Incorporated (NASDAQ:CORT)

Upside Potential as of January 12, 2026: 154.28%

Market Capitalization as of January 12, 2026: $3.93 billion 

Number of Hedge Fund Holders: 28

According to an Investing.com report, William Guyer, Chief Development Officer at Corcept Therapeutics Incorporated (NASDAQ:CORT), sold 20,000 shares of common stock valued at $703,656 on January 6.

Earlier on January 2, Swayampakula Ramakanth, an analyst at H.C. Wainwright, trimmed the price target on Corcept Therapeutics Incorporated (NASDAQ:CORT) to $90 from $145, while maintaining a ‘Buy’ rating on the stock. Slightly below the median price target of $95, the revised price target suggests an upside potential of nearly 141%.

According to TheFly, this downward stance follows the FDA’s Complete Response Letter (CRL) centering on the new drug application for relacorilant as a treatment for hypercortisolism in Cushing’s syndrome. The research firm reports that although the FDA acknowledged the company’s pivotal GRACE trial, which achieved the primary endpoint, and the GRADIENT trial provided some confirmatory evidence, the regulatory agency still requires additional confirmatory evidence to evaluate the benefit-risk profile of relacorilant. That said, the stock is currently trading at the lowest levels since its abrupt drop on December 31, 2025.

In response, Corcept Therapeutics Incorporated (NASDAQ:CORT) plans to request a Type A meeting with the FDA to clear the path ahead. This will give management the opportunity to provide insights into their strategy by the end of the first quarter of this year. H.C. Wainwright expects a three-year delay in the rollout of relacorilant, with a new expected launch in the first quarter of 2029.

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a California-based company that discovers and develops solutions for serious endocrinologic, oncologic, metabolic, and neurologic disorders. Founded in 1998, the company is committed to unlocking “the potential of cortisol modulation.”

While we acknowledge the potential of CORT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CORT and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.